Study of Sintilimab, a PD-1 Inhibitor, as Second-line Treatment in FH-deficient Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma; FH-deficient; Sintilimab Intervention: Drug: Sintilimab Sponsor: West China Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hospitals | Kidney Cancer | Renal Cell Carcinoma | Research | Study